Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLX-100
- Development stage
- Unknown
- Lead developer
- Glycologix
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravesical
01
Overview
GLX-100 is a novel, crosslinked glycosaminoglycan (GAG) biopolymer designed to closely replicate the natural protective barrier of the bladder wall. It is intended for intravesical instillation as a glycosaminoglycan replenishment therapy (GRT) for interstitial cystitis/bladder pain syndrome (IC/BPS). The drug acts locally by binding to and restoring the damaged urothelial layer, thereby improving bladder impermeability and reducing symptoms such as pain, urgency, frequency, and nocturia. Unlike current single-chain GAG therapies with limited efficacy and residence time, GLX-100’s crosslinked structure provides higher affinity for the bladder surface and longer residence time. There is no systemic absorption. Developed by Glycologix, it has completed Phase 1b studies showing promising safety/efficacy results and is in ongoing clinical development[1][2][3][8].
- Brand names
- GLX-100GLX100GLX 100
- Other names
- SuperGAGcrosslinked chondroitin sulfate biopolymer
Beyond the preview
Go deeper on GLX-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLX-100.